DAJY(002030.CN)

中文

行情走势

最新价

--

最高价

--

涨跌额

--

最低价

--

涨跌幅

--

成交量

--

今开盘

--

成交额

--

昨收盘

--

行情时间

--

Introduction

Relying on the scientific research platform of Sun Yat-sen University, Da An Gene Co.,Ltd. Of Sun Yat-senUniversity is a high-tech biomedical enterprise with molecular diagnostic technology as the leading factor, integrating the research and development, production and sales of clinical testing reagents and instruments as well as the clinical testing services of national chain independent medical laboratories. The company was listed in Shenzhen Stock Exchange in August 2004, becoming the first listed company in the university-run industry of Guangdong Province.

History

Da An Gene Co.,Ltd. Of Sun Yat-sen University was established on August 17, 1988 with the approval of Guangzhou Municipal Administration for Industry and Commerce.

On January 26, 1991, Zhongshan Audiovisual Technology Co., LTD., Zhongshan Medical University Zhixin Service Co., LTD., And Guangdong Kesida Medical Instrument Industrial Co., LTD., Dongshan District, Guangzhou, were merged into Science and Technology Development Company of Zhongshan Medical University.

On December 8, 1999, Science and Technology Development Company of Sun Yat-sen Medical University was changed into Science and technology Development Company of Sun Yat-sen Medical University.

In December 2000, Science and Technology Development Co., LTD of Sun Yat-sen Medical University was renamed As Daan Gene Co., LTD of Sun Yat-sen Medical University with the approval of Guangzhou Industrial and Commercial Administration Bureau.

On March 8, 2001, Sun Yat-sen University Of Medical Sciences Da 'an Gene Co., Ltd. was changed into Sun Yat-sen University of Medical Sciences Da 'an Gene Co., LTD.

Due to the merger of Sun Yat-sen University and Sun Yat-sen University, the company was renamed Da An Gene Co.,Ltd. Of Sun Yat-sen University on December 13, 2001.

In July 2004, Daan gene was listed on the Shenzhen Stock Exchange.

In 2014, it was announced that its holding subsidiary, Guangzhou Darui Biotechnology Co., Ltd. would apply for listing in the national sme share transfer system when conditions are ripe.

Business

There are more than 70 holding companies, covering molecular diagnostic technology, immunodiagnostic technology, biochemical diagnostic technology, medical devices, testing services, healthy birth and healthy childbearing, food safety and industrial investment, etc., with independent professional companies in each field. PCR nucleic acid diagnosis technology, such as chip platform, sequencing platform, ELISA platform.

The company's business is divided into instruments, reagents, services. In the field of reagents, the company specializes in immunological and molecular diagnostic reagents. In terms of instruments, it mainly includes high-end PCR analyzer, TRF analyzer, full-automatic nucleic acid hybridization analyzer, and other analytical instruments and equipment in clinical, scientific research, public health and other fields. In the service field, there are 8 independent laboratories. In the reagent income, hepatitis reagent income accounts for about 40%, other such as tumor, respiratory tract, healthy birth and healthy breeding, venereal diseases reagent income accounts for about 60%.

Among them, the company's biochemical detection platform is Mainly Datai Biology, and the immunization platform is mainly the parent company of Darui Biology, Zhongshan Biology and Daan Gene. Zhongshan Biology is mainly enzymatic immunoassay and colloidal gold method, which are the traditional methods of immunoassay. Darry Bio mainly has chemiluminescence and time-resolved immunofluorescence, which are relatively high-end methods in immune detection methods, while Xiamen Youmike mainly deals in chemiluminescence analytical instruments.

In terms of immunoreagents, the company mainly has three platforms: Zhongshan Biology, Darui Biology and Xiamen Umaike; Zhongshan biologic mainly produces enzyme-linked immunoassay and colloidal gold immunoassay reagent.

PCR business is concentrated in the parent company of Daan Gene, and PCR reagents account for about 70% of reagent revenue. From the technical platform analysis, PCR reagents include PCR-fluorescent probe, PCR-sequencing, PCR-reverse dot hybridization and other technical platforms based on PCR technology.

电子城 福田汽车 翰宇药业 华邦健康 完美世界 华海药业 锡业股份 桂林旅游 准油股份